Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6JKH

The NAD+-bound form of human NSDHL

Summary for 6JKH
Entry DOI10.2210/pdb6jkh/pdb
DescriptorSterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating, NICOTINAMIDE-ADENINE-DINUCLEOTIDE (3 entities in total)
Functional Keywordscholesterol, dehydrogenase, oxidoreductase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight55839.02
Authors
Kim, D.,Lee, S.J.,Lee, B. (deposition date: 2019-02-28, release date: 2020-03-04, Last modification date: 2023-11-22)
Primary citationKim, D.G.,Cho, S.,Lee, K.Y.,Cheon, S.H.,Yoon, H.J.,Lee, J.Y.,Kim, D.,Shin, K.S.,Koh, C.H.,Koo, J.S.,Choi, Y.,Lee, H.H.,Oh, Y.K.,Jeong, Y.S.,Chung, S.J.,Baek, M.,Jung, K.Y.,Lim, H.J.,Kim, H.S.,Park, S.J.,Lee, J.Y.,Lee, S.J.,Lee, B.J.
Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity.
Cell.Mol.Life Sci., 78:207-225, 2021
Cited by
PubMed Abstract: NAD(P)-dependent steroid dehydrogenase-like (NSDHL), an essential enzyme in human cholesterol synthesis and a regulator of epidermal growth factor receptor (EGFR) trafficking pathways, has attracted interest as a therapeutic target due to its crucial relevance to cholesterol-related diseases and carcinomas. However, the development of pharmacological agents for targeting NSDHL has been hindered by the absence of the atomic details of NSDHL. In this study, we reported two X-ray crystal structures of human NSDHL, which revealed a detailed description of the coenzyme-binding site and the unique conformational change upon the binding of a coenzyme. A structure-based virtual screening and biochemical evaluation were performed and identified a novel inhibitor for NSDHL harboring suppressive activity towards EGFR. In EGFR-driven human cancer cells, treatment with the potent NSDHL inhibitor enhanced the antitumor effect of an EGFR kinase inhibitor. Overall, these findings could serve as good platforms for the development of therapeutic agents against NSDHL-related diseases.
PubMed: 32140747
DOI: 10.1007/s00018-020-03490-2
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon